Prosecution Insights
Last updated: October 01, 2026

Jiangsu Genscript Probio Biotech Co. Ltd.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Jiangsu Genscript Probio Biotech Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and 1 distinct art unit. KODYE LEE ABBOTT is the busiest examiner, responsible for the 1 pending office action. The current prosecution state is highly focused, with only 1 pending office action active. This centralized structure allows the applicant to concentrate all efforts on a single examiner and a single set of art unit guidelines, which can lead to a more efficient prosecution process.

Because this action is assigned to 1 distinct examiner and 1 distinct art unit, the applicant's primary task is to address the specific concerns of KODYE LEE ABBOTT. There are no other examiners or art units involved, which simplifies the strategic approach within the Biotechnology & Pharmaceuticals technology area. Practitioners should focus on the examiner's specific technical expertise to craft effective responses. With only 1 pending office action, the company can ensure that its legal resources are used effectively to secure this particular patent asset, as the entire portfolio's current success depends on this single interaction.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
0
Medium (0%)
1
Easy (100%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§112 only1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
ABBOTT, KODYE LEE 1 53.1% +71.4%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18257802 HEK293T CELL STRAIN HAVING HIGH DISPERSIBILITY AND SCREENING METHOD THEREFOR ABBOTT, KODYE LEE —

Top Art Units

Art UnitApps
1634 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18257802 HEK293T CELL STRAIN HAVING HIGH DISPERSIBILITY AND SCREENING METHOD THEREFOR ABBOTT, KODYE LEE 1634 §112 Non-Final OA — Pending Jun 15, 2023

Managing Jiangsu Genscript Probio Biotech Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month